Since the first reports in the late 1970s on transition metal complexes contain- ing pincer-type ligands—named after the particular coordination mode of these ligands—these systems have at- tracted increasing interest owing to the unusual properties of the metal centers imparted by the pincer ligand. Typical- ly, such a ligand comprises an anionic aryl ring which is ortho,ortho-disubsti- tuted with heteroatom substituents, for example, CH2NR2 ,C H 2PR2 or CH2SR, which generally coordinate to the met- al center, and therefore support the MC s bond. This commonly results in a terdentate and meridional coordina- tion mode consisting of two metalla- cycles which share the MC bond. Detailed studies of the formation and the properties of a large variety of pincers containing platinum group metal complexes have provided direct access to both a fundamental under- standing of a variety of reactions in organometallic chemistry and to a range of new applications of these complexes. The discovery of alkane dehydrogenation catalysts, the mecha- nistic elucidation of fundamental transformations (for example, CC bond activation), the construction of the first metallodendrimers for sustain- able homogeneous catalysis, and the engineering of crystalline switches for materials processing represent only a few of the many highlights which have emanated from these numerous inves- tigations. This review discusses the synthetic methodologies that are cur- rently available for the preparation of platinum group metal complexes con- taining pincer ligands and especially emphasizes different applications that have been realized in materials science such as the development and engineer- ing of sensors, switches, and catalysts.

Platinum Group Organometallics Based on “Pincer” Complexes: Sensors, Switches, and Catalysts

Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and melanoma. Unfortunately its continued use is greatly limited by severe dose limiting side effects and intrinsic or acquired drug resistance. Over the last 30 years, 23 other platinum-based drugs have entered clinical trials with only two (carboplatin and oxaliplatin) of these gaining international marketing approval, and another three (nedaplatin, lobaplatin and heptaplatin) gaining approval in individual nations. During this time there have been more failures than successes with the development of 14 drugs being halted during clinical trials. Currently there are four drugs in the various phases of clinical trial (satraplatin, picoplatin, Lipoplatin™ and ProLindac™). No new small molecule platinum drug has entered clinical trials since 1999 which is representative of a shift in focus away from drug design and towards drug delivery in the last decade. In this perspective article we update the status of platinum anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued during clinical trials, and discuss the results in the context of where we believe the field will develop over the next decade.

/pdf/the-status-of-platinum-anticancer-drugs-in-the-clinic-and-in-pmbsuzji3m.pdf

The status of platinum anticancer drugs in the clinic and in clinical trials.

The demonstration in the 1960's that cis-diamminedichloroplatinum(II), or cisplatin, inhibits cellular division of Escherichia coli1 led to the subsequent discovery that this simple coordination compound is also an effective antitumor agent in mouse models.2 Subsequent studies validated cisplatin as an effective anticancer agent in humans as well,3–7 and FDA approval of cisplatin for the treatment of metastatic ovarian and testicular cancers was granted in 1978.8 Its introduction as a chemotherapeutic agent significantly improved the survival outlook for many cancer patients; the cure rate for testicular cancer before the approval of cisplatin was less than 10%, significantly lower than the 90% cure rate attained with modern platinum chemotherapy.9,10

Cisplatin kills cancer cells primarily by cross-linking DNA and inhibiting transcription.11 The chemical origin of this process begins when cisplatin enters the cell and undergoes aquation involving loss of one or both chloride ligands. The resulting platinum(II) aqua complexes are potent electrophiles that readily react with a number of biological ligands with loss of the bound water molecules. The purine bases of nucleic acids are strongly nucleophilic at the N7 position. Thus, cisplatin binds readily to DNA, forming primarily bifunctional adducts with loss of both chloride ligands. The major cisplatin-DNA adduct is the intrastrand 1,2-d(GpG) cross-link, which accounts for 60–65% of the bound platinum.12 The resulting Pt-DNA adducts, which distort and bend the DNA structure,13–15 impede transcription.16 The downstream effects of transcription inhibition ultimately lead to cell death.

Despite its great curative success in testicular cancer, cisplatin is not universally effective in other cancer types and induces a number of toxic side effects.17–19 Additionally, certain cancers are resistant to cisplatin therapy. This resistance is either intrinsic or developed during prolonged treatment.20,21 To circumvent these problems, new platinum complexes have been pursued and investigated for their antitumor properties. Although well over a thousand complexes have been prepared and tested thus far,22 only two other platinum drugs are approved for clinical use worldwide, and three additional compounds are approved for regional use in Asia.23 These complexes, displayed in Chart 1, operate with a mechanism of action similar to that of cisplatin, which involves DNA binding and transcription inhibition.






Open in a separate window


Chart 1


Chemical structures of the clinically used platinum-based anticancer drugs. The top three complexes, cisplatin, carboplatin, and oxaliplatin, are approved for use worldwide. The bottom three complexes, nedaplatin, lobaplatin, and heptaplatin, are approved for use in Japan, China, and Korea, respectively.

/pdf/synthetic-methods-for-the-preparation-of-platinum-anticancer-4et0np31b8.pdf

Synthetic Methods for the Preparation of Platinum Anticancer Complexes

We report the synthesis of novel acid-responsive therapeutic nanoparticles (NPs) with sub-100 nm size consisting of polymer−cisplatin conjugates. The uniqueness of these drug delivery polymeric NPs lies in the covalent conjugation of each cisplatin drug to the hydrophobic segment of two biocompatible diblock copolymer chains through a hydrazone bond, resulting in highly differential drug release profile at different environmental acidity. We demonstrate that the synthesized polymer−cisplatin conjugates can readily precipitate to form sub-100 nm NPs in aqueous solution due to their very low critical micelle concentration (CMC). The resulting NPs show well-controlled cisplatin loading yield, excellent acid-responsive drug release kinetics, and enhanced in vitro cytotoxicity against ovarian cancer cells as compared to free cisplatin. As an environmentally sensitive drug delivery vehicle, these NPs can potentially minimize the drug loss during NP circulation in the blood, where the pH value is neutral, and tr...

/pdf/polymer-cisplatin-conjugate-nanoparticles-for-acid-4j1iejm8mr.pdf

Polymer--cisplatin conjugate nanoparticles for acid-responsive drug delivery.

https://www.jbc.org/content/273/24/14721.full.pdf

Cisplatin Binding Sites on Human Albumin

The structure of the antitumor complex cis-(diammino) (1,1-cyclobutanedicarboxylato)-Pt(II): X ray and nmr studies

Resolution des structures des trois isomeres cis cis trans, trans trans trans et cis trans cis et caracterisation du premier en solution par spectrometrie RMN- 15 N et 195 Pt. Coordination octaedrique autour des atomes Pt dans les trois cas

Ismail M. Ismail

Papers

The structure of the antitumor complex cis-(diammino) (1,1-cyclobutanedicarboxylato)-Pt(II): X ray and nmr studies

Crystal and molecular structure of three isomers of dichlorodiamminedihydroxoplatinum(IV): cis-trans isomerization on recrystallization from water

Effects of chemical shift anisotropy and 14N coupling on the 1H and 195Pt nuclear magnetic resonance spectra of platinum complexes

195Pt- and15N-NMR Studies of Antitumor Complexes

Kinetic studies on the diaqua form of cis-platin and various nucleobases.